Evaluating Future Steps for Investigating Seleno-L-Methionine in RCC
Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center, discusses the next steps after the phase 1 trial (NCT02535533) of seleno-L-methionine (SLM) in combination with axitinib (Inlyta) as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC).
Zakharia says that 1 of the observations they had while investigating this clinical trial was that the higher the blood concentration was with SLM, the better response patients had. Although this was a small cohort of patients, the investigators amended the protocol in the study to allow patients with ccRCC to be treated based on their body surface area, and this topic is still ongoing among the authors.
If they continue to see efficacy in the phase 1 data, the next step will be to start a randomized clinical trial of axitinib as the standard of care and the combination of axitinib and SLM in patients with advanced metastatic ccRCC, according to Zakharia.
<< View more resources and information regarding renal cell carcinoma
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
